Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

Benzinga Newsdesk www.benzinga.com Negative 80.8%

Neg 80.8% Neu 0% Pos 0%

Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.